In vitro-in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps

International Journal of Pharmaceutics

Volumn 451, Issue 1-2, 2013, Pages 57-66

  Hill, A ^a   Geissler S ^b   Meyring, M ^c   Hecht, S ^c   Weigandt, M ^b   Mader K ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Merck Serono GmbH   (Germany)

^c Merck Serono   (Germany)

Author keywords

In vivo; Nanosuspensions; Osmotic pumps; Preclinical research; Viscosity

Indexed keywords

1,3 DICYCLOHEXYLUREA; NANOPARTICLE; POLOXAMER; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DYNAMIC LIGHT SCATTERING; FEMALE; FLOW KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMPLANTABLE OSMOTIC PUMP; IMPLANTABLE PUMP; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MAXIMUM PLASMA CONCENTRATION; MOUSE; NANOSUSPENSION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSPENSION; ULTRAVIOLET SPECTROSCOPY; VISCOSITY;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; DRUG STABILITY; FEMALE; INJECTIONS, SUBCUTANEOUS; LIGHT; MICE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; OSMOSIS; PHARMACEUTICAL PREPARATIONS; POLOXAMER; RHEOLOGY; SCATTERING, RADIATION; SOLUBILITY; SUSPENSIONS; TIME FACTORS; VISCOSITY;

EID: 84877872632     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.04.060     Document Type: Article

References (45)

1. L. Aarons, M. Rowland, and L.P. Balant Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies Eur. J. Clin. Pharmacol. 49 1996 251 254
2. H.S.M. Ali, P. York, and A.M.A. Ali Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling J. Control. Release 149 2011 175 181
3. Z. Amoozgar, and Y. Yeo Recent advances in stealth coating of nanoparticle drug delivery systems WIREs Nanomed. Nanobiotechnol. 4 2012 219 233
4. K. Aukland, and H.O. Fadnes Protein concentration of interstitial fluid collected from rat skin by a Wick method Acta Physiol. Scand. 88 1973 350 358
5. L. Baert, G. van 't Klooster, and W. Dries Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment Eur. J. Pharm. Biopharm. 72 2009 502 508
6. K.H. Bleicher, H.J. Bohm, and K. Müller Hit and lead generation: beyond high-throughput screening Nat. Rev. Drug Discov. 2 2003 369 378
7. Z. Cai, Y. Wang, and L.J. Zhu Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs Curr. Drug Metab. 11 2010 197 207
8. P.C. Chiang, Y. Ran, and K.J. Chou Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3-dicyclohexylurea in rats. Preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery Nanoscale Res. Lett. 6 2011 1 9
9. E.A. Deitch Gut lymph and lymphatics: a source of factors leading to organ injury and dysfunction Ann. N. Y. Acad. Sci. 1207 2010 E103 E111
10. L. Di, P.V. Fish, and T. Mano Bridging solubility between drug discovery and development Drug Discov. Today 17 2012 486 495
11. B. Eckenhoff, and S.I. Yum The osmotic pump: novel research tool for optimizing drug regimens Biomater 2 1981 89 97
12. Eliaz, R., Yuanpeng, Z., Rohloff, C., et al., 2005. Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle. WO patent 2005/048952 A2.
13. L. Gao, G. Liu, and J. Ma Drug nanocrystals: in vivo performances J. Control. Release 160 2012 418 430
14. L. Garvey, and A. Winston Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor Expert Opin. Investig. 18 2009 1035 1041
15. R. Gullapalli, A. Wong, and E. Brigham Development of ALZET osmotic pump compatible solvent compositions to solubilize poorly soluble compounds for preclinical studies Drug Deliv. 19 2012 239 246
16. A. Hill, S. Geissler, and M. Weigandt Controlled delivery of nanosuspensions from osmotic pumps: Zero order and non-zero order kinetics J Control. Release 158 2012 403 412
17. K. Hirano, and H. Yamada Studies on the absorption of practically water-insoluble drugs following injection VI: subcutaneous absorption from aqueous suspensions in rats J. Pharm. Sci. 71 1982 500 505
18. K. Hirano, and H. Yamada Studies on the absorption of practically water-insoluble drugs following injection VII. Plasma-concentration after different subcutaneous doses of A drug in aqueous suspension in rats J. Pharm. Sci. 72 1983 602 607
19. R. Huggenberger, and M. Detmar The cutaneous vascular system in chronic skin inflammation J. Investig. Dermatol. Symp. Proc. 15 2011 24 32
20. P. Kayaert, and G. Van den Mooter An investigation of the adsorption of hydroxypropylmethyl cellulose 2910 5 mPa s and polyvinylpyrrolidone K90 around Naproxen nanocrystals J. Pharm. Sci. 101 2012 3916 3923
21. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug. Discov. 3 2004 711 716
22. A.C. Ludolph, C. Bendotti, and E. Blaugrund Guidelines for preclinical animal research in ALS/MND A consensus meeting Acta Oncol. 11 2010 38 45
23. D. McLennan Subcutaneous drug delivery and the role of the lymphatics Drug Discov. Today 2 2005 89 96
24. D.W. Mendenhall Trends in formulation science: building in developability AAPS Newsmagazine 13 2001
25. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanosizing: a formulation approach for poorly-water-soluble compounds Eur. J. Pharm. Sci. 18 2003 113 120
26. A. Michna, Z. Adamczyk, and M. Ocwieja Kinetics of silver nanoparticle deposition onto poly(ethylene imine) modified mica determined by AFM and SEM measurements Colloids Surf. A377 2011 261 268
27. P.R. Mishra, S.L. Al, and R.H. Müller Production and characterization of Hesperetin nanosuspensions for dermal delivery Int. J. Pharm. 371 2009 182 189
28. S.M. Moghimi, A.C. Hunter, and T.L. Andresen Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective Annu. Rev. Pharmacol. Toxicol. 52 2012 481 503
29. S. Neervannan Preclinical formulations for discovery and toxicology: physicochemical challenges Expert Opin. Drug Metab. Toxicol. 2 2006 715 731
30. C. Oussoren, and G. Storm Liposomes to target the lymphatics by subcutaneous administration Adv. Drug Deliv. Rev. 50 2001 143 156
31. B.J. Palla, and D.O. Shah Stabilization of high ionic strength slurries using the synergistic effects of a mixed surfactant system J. Colloid Interface Sci. 223 2000 102 111
32. L. Peltonen, and J. Hirvonen Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods J. Pharm. Pharmacol. 62 2010 1569 1579
33. B. Rabinow Pharmacokinetics of drugs administered in nanosuspension Discov. Med. 5 2005 74 79
34. B. Rabinow, J. Kipp, and P. Papadopoulos Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat Int. J. Pharm. 339 2007 251 260
35. C. Servais, R. Jones, and I. Roberts The influence of particle size distribution on the processing of food J. Food Eng. 51 2002 201 208
36. S. Stegemann, F. Leveiller, and D. Franchi When poor solubility becomes an issue: from early stage to proof of concept Eur. J. Pharm. Sci. 31 2007 249 261
37. J. Urquhart, J.W. Fara, and K.L. Willis Rate-controlled delivery systems in drug and hormone research Annu. Rev. Pharmacol. Toxicol. 24 1984 199 236
38. G. van't Klooster, E. Hoeben, H. Borghys, A. Looszova, M.P. Bouche, F. van Velsen, and L. Baert Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation Antimicrob. Agents Chemother. 54 2010 2042 2050
39. S. Venkatesh, and R.A. Lipper Role of the development scientist in compound lead selection and optimization J. Pharm. Sci. 89 2000 145 154
40. H. Wiig, R.K. Reed, and O. Tenstad Interstitial fluid pressure, composition of interstitium, and interstitial exclusion of albumin in hypothyroid rats Am. J. Physiol. Heart Circ. Physiol. 278 2000 H1627 H1639
41. J. Wong, A. Brugger, and A. Khare Suspensions for intravenous (IV) injection: a review of development preclinical and clinical aspects Adv. Drug Deliv. Rev. 60 2008 939 954
42. X. Xu, Y.S. Wang, and R.Y. Chen Formulation and pharmacokinetic evaluation of tetracycline-loaded solid lipid nanoparticles for subcutaneous injection in mice Chem. Pharm. Bull. 59 2011 260 265
43. M. Zhao, G. Thuret, and S. Piselli Use of poloxamers for deswelling of organ-cultured corneas Invest. Ophth. Vis. Sci. 49 2008 550 559
44. J.R. Zingerman, J.R. Cardinal, and R.T. Chern The in vitro and in vivo performance of an osmotically controlled delivery system-IVOMEC SR bolus J. Control. Release 47 1997 1 11
45. J. Zuidema, F. Kadir, and T. Hac Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II) Int. J. Pharm. 105 1994 189 207